Study type: Human research · Status: Verified against declared source
Cerebrolysin induces hair repigmentation associated to MART-1/Melan-A reactivation
2022
Study scale: The most frequently reported self-limited adverse reactions due to Cerebrolysin are vertigo or dizziness, headache, nausea, and increased sweating, as stated in the Product Information Label.
Abstract only: Open source record
Product or molecular entity relationships
- Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
The most frequently reported self-limited adverse reactions due to Cerebrolysin are vertigo or dizziness, headache, nausea, and increased sweating, as stated in the Product Information Label.
Methods
The patients who qualified for study entry received the study medication using a modified Cerebrolysin protocol as follows.
Scale or participants
The most frequently reported self-limited adverse reactions due to Cerebrolysin are vertigo or dizziness, headache, nausea, and increased sweating, as stated in the Product Information Label.
Key findings
Hair graying, a prototypical sign of human aging, is a progressive loss of pigmentation from growing hair shafts caused by disease and as a side effect of medications.
Limitations and uncertainty
Hair graying, a prototypical sign of human aging, is a progressive loss of pigmentation from growing hair shafts caused by disease and as a side effect of medications.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.